ClinicalTrials.gg
Status unknownNCT05185362PEC-ALLUpdated Jan 11, 2022

Epidemiology of Pecan Nut Allergy

An observational study in Allergic Reaction, sponsored by University Hospital, Montpellier. Status unknown at 1 site in France. Open to participants aged 5 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by University Hospital, Montpellier · Observational

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50
Ages
5 Years to 70 Years
Sex
All
01

Study summary

IgE-mediated food allergy can manifest with reactions ranging from hives to anaphylactic shock. The diagnosis is based on the confirmation of sensitization to the food allergen by skin tests (prick) and the determination of specific IgE directed against the food source and molecular allergens. The gold standard remains the oral provocation test, which is performed in a hospital environment. Once the diagnosis is made, an elimination diet is still considered as the cornerstone of treatment for most food allergies.

While some allergies, such as cow's milk or egg, tend to resolve spontaneously, others, such as allergy to pecan nuts, show a tendency to be persistent. In addition, pecan allergy is often characterized by potentially serious clinical reactions, compared to other foods, which can even be life threatening. In our clinical practice, the investigators found that patients with allergies to pecan nuts often present with severe hypersensitivity reactions when challenged orally to this food. Beyond this information, there are few studies regarding pecans. The investigators decided to retrospectively evaluate the results of oral food challenge and of the allergy work-up in our patients sensitized and allergic to pecan nuts, to better understand the current epidemiology of such food allergy.

02

Conditions studied

  • Allergic Reaction

Keywords

  • Sensitization to pecan nut (specific IgE and/or skin prick tests)
  • Challenge proven pecan allergy
  • Allergic Comorbidities
  • Oral food challenge
  • Anaphylaxis
03

In context

Hypersensitivity

1,055 studies on the registry are indexed under Hypersensitivity; 149 are open to participants now.

This study's planned enrollment of 50 is below the median of 166 across 327 observational studies indexed under Hypersensitivity.

Browse Hypersensitivity studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 224 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients consulting in the Allergy Unit of the Arnaud de Villeneuve Hospital, sensitized to pecan nut, and having undergone an oral food challenge to this food allergen

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients assessed for pecan allergy, through oral food challenge, from January 2000 to december 2021, at the University Hospital of Montpellier
  • Patients with a positive skin prick test and/or positive specific IgE to pecan nut

Exclusion criteria

Exclusion criteria:

  • Patients not affiliated to French Social Security
  • Patients not capable of understanding French
  • Patients sensitized to pecan nut, who did not perform an oral food challenge to this food allergen
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalence of challenge-proven pecan allergy

    Prevalence of challenge-proven pecan allergy in sensitized patients

    Time frame: day 1

Secondary outcomes

  1. Epidemiological characteristics of pecan allergic patient

    Epidemiological characteristics of pecan allergic patient(cypress pollen-induced allergic rhinitis or food allergy to peach)

    Time frame: day 1

  2. cut-off of specific IgE

    cut-off of specific IgE and of results of prick test to predict pecan allergy in sensitized and allergic patients

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
  • Uhmontpellier
    Montpellier, 34295, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — NC

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Jan 2022, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2021
First posted
Jan 11, 2022
StartActual
Nov 1, 2021
Primary completionEst.
Jan 1, 2022
CompletionEst.
Apr 1, 2022
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05185362
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
Nov 1, 2021
Primary completion
Jan 1, 2022 (estimated)
Completion
Apr 1, 2022 (estimated)
Last update
Jan 11, 2022

Study contacts

Davide CAIMMI, MD
Contact
davide.caimmi@gmail.com
467336112 ext. 33
Audrey GOPAL, MD
Contact
gopal@chu-montpellier.fr
467336107
Davide CAIMMI
study director · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion